Trial Profile
Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Biomarker; Therapeutic Use
- 22 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Nov 2008 New trial record.